The pooled RR for HF rehospitalization was 0.76 (95% CI: 0.71 to 0.81), indicating a 24% relative reduction in the risk of rehospitalization with SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and hydrops fetalis.